ACADIA Pharmaceuticals/$ACAD
1D1W1MYTD1Y5YMAX
Capital at risk
About ACADIA Pharmaceuticals
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
- Ticker
- $ACAD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 797
- Headquarters
- San Diego, United States
- Website
- www.acadia.com
ACAD Metrics
BasicAdvanced
$4.7B
12.44
$2.21
0.85
-
Price and volume
Market cap
$4.7B
Beta
0.85
52-week high
$30.96
52-week low
$19.69
Average daily volume
1.5M
Financial strength
Current ratio
3.388
Quick ratio
3.107
Long term debt to equity
0.046
Total debt to equity
0.046
Profitability
EBITDA (TTM)
98.228
Gross margin (TTM)
62.06%
Net profit margin (TTM)
33.42%
Operating margin (TTM)
7.59%
Effective tax rate (TTM)
-213.50%
Revenue per employee (TTM)
$1,430,000
Management effectiveness
Return on assets (TTM)
3.64%
Return on equity (TTM)
35.74%
Valuation
Price to earnings (TTM)
12.444
Price to revenue (TTM)
4.104
Price to book
3.61
Price to tangible book (TTM)
3.93
Price to free cash flow (TTM)
32.087
Free cash flow yield (TTM)
3.12%
Free cash flow per share (TTM)
0.855
Growth
Revenue change (TTM)
11.75%
Earnings per share change (TTM)
66.40%
3-year revenue growth (CAGR)
27.38%
10-year revenue growth (CAGR)
143.25%
3-year earnings per share growth (CAGR)
47.31%
10-year earnings per share growth (CAGR)
1.35%
What the Analysts think about ACAD
Analyst ratings (Buy, Hold, Sell) for ACADIA Pharmaceuticals stock.
Analyst projections of the future price of ACADIA Pharmaceuticals stock.
Bulls say / Bears say
Acadia’s DAYBUE net sales surged 30% year-over-year to $125 million in Q2 2026, while NUPLAZID net sales grew 9% to $183 million, underscoring strong commercial momentum across both franchises. (Business Wire)
Acadia raised its full-year 2026 total revenue guidance to $1.24–$1.30 billion, reflecting increased DAYBUE guidance of $480–$510 million alongside reaffirmed NUPLAZID guidance, signaling management’s confidence in continued growth. (Business Wire)
The EMA’s CHMP adopted a positive opinion recommending marketing authorization for DAYBU (trofinetide) in the EU, positioning Acadia to become the first to market a Rett syndrome treatment in Europe and expand its addressable market. (Investing.com)
The upcoming topline results from the Phase 2 RADIANT study of remlifanserin in Alzheimer’s disease psychosis, expected in September–October 2026, present binary clinical risk that could materially impact Acadia’s pipeline valuation if the data are not supportive. (Business Wire)
Acadia’s revenues remain highly concentrated in two products—DAYBUE and NUPLAZID—which together accounted for the entirety of its $308 million in Q2 2026 sales, exposing the company to significant product-specific risk. (Business Wire)
Acadia acknowledges that if it fails to obtain and maintain patent protection, it may face generic competition prior to existing expiration dates, which could erode its competitive advantage and materially impact revenues. (SEC 10-Q)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2026.
ACAD Financial Performance
Revenues and expenses
ACAD Earnings Performance
Company profitability
Upcoming events
No upcoming events
ACAD News
AllArticlesVideos
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
Business Wire4 weeks ago
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer's Data
MarketBeat1 month ago
ACADIA Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat2 months ago
Funds containing ACAD
AllUSDEURGBP
Fund name | Fund size | $ACAD weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.36% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.36% |
iShares Healthcare Innovation£DRDR | £1B | 0.36% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.31% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.31% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.